BBOT To Participate In Upcoming Investor Healthcare Conferences

2026-09-01 04:16:39

(MENAFN- GlobeNewsWire - Nasdaq) SOUTH SAN FRANCISCO, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced that members of its leadership team will participate in upcoming investor conferences.

Details of the company's participation are as follows:

Cantor Global Healthcare Conference 2026
Wednesday, September 9, 2026, at 9:45 a.m. ET

Citi's 2026 Biopharma Back to School Conference
Thursday, September 10, 2026, at 3:00 p.m. ET

Morgan Stanley 24th Annual Global Healthcare Conference
Tuesday, September 15, 2026, at 1:50 p.m. ET

Live webcasts of the presentations will be accessible on the“ Events . Replays of the webcasts will be available for at least 90 days following the event.

About BBOT
BBOT is a clinical-stage biopharmaceutical company advancing a next-generation pipeline of novel small molecule therapeutics targeting RAS and PI3Kα malignancies. BBOT has the goal of improving outcomes for patients with cancers driven by the two most prevalent oncogenes in human tumors. For more information, please visit and follow us on LinkedIn
CONTACT: BBOT Contacts: Investor Contact: BBOT... Media Contact: Inizio Evoke Comms...
a-BridgeBio-Onc.png' referrerpolicy='no-referrer-when-downgrade' />

MENAFN01092026004107003653ID1111609001

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.

BBOT To Participate In Upcoming Investor Healthcare Conferences

More Story